ABSTRACT
Description: Liprolog is a fast-acting insulin analogue (see also the monograph for the product Humalog). It differs from the human insulin in an inversion of the natural proline-lysine sequence at positions 28 and 29 of the insulin B chain. It is produced by recombinant DNA technology in a modified Escherichia coli strain. The final product is presented as a solution for subcutaneous injection in vials and cartridges for multidose devices (Liprolog pen). Formulations containing 25% (Liprolog Mix 25) or 50% (Liprolog Mix 50) of insulin lispro in soluble form and 75 or 50%, respectively, of insulin lispro crystallized with protamine sulphate were also available.
